Holen Sie sich die Stockscreener-App
3.615
2.43%
-0.085
Schlusskurs vom Vortag:
$3.70
Offen:
$3.68
24-Stunden-Volumen:
2.15M
Relative Volume:
1.06
Marktkapitalisierung:
$618.92M
Einnahmen:
$25.55M
Nettoeinkommen (Verlust:
$-341.97M
KGV:
-1.2911
EPS:
-2.8
Netto-Cashflow:
$-304.44M
1W Leistung:
-2.70%
1M Leistung:
+9.39%
6M Leistung:
-19.42%
1J Leistung:
-56.06%
1-Tages-Spanne:
$3.54
$3.75
1-Wochen-Bereich:
$3.54
$3.88
52-Wochen-Spanne:
$1.775
$10.72
Relay Therapeutics Inc Stock (RLAY) Company Profile
Firmenname
Relay Therapeutics Inc
Sektor
Branche
Telefon
617-370-8837
Adresse
399 BINNEY STREET, CAMBRIDGE
Vergleichen Sie RLAY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
3.61 | 641.20M | 25.55M | -341.97M | -304.44M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.34 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.53 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.59 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
596.80 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
305.41 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-17 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-09-10 | Fortgesetzt | Goldman | Buy |
| 2024-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-05-10 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-04-20 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-04-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-04-13 | Eingeleitet | Raymond James | Outperform |
| 2023-02-03 | Eingeleitet | Oppenheimer | Outperform |
| 2022-09-30 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-02 | Eingeleitet | Stifel | Buy |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-02-01 | Eingeleitet | Berenberg | Buy |
| 2021-07-21 | Eingeleitet | BofA Securities | Buy |
| 2020-12-15 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-11-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-08-10 | Eingeleitet | Cowen | Outperform |
| 2020-08-10 | Eingeleitet | Goldman | Buy |
| 2020-08-10 | Eingeleitet | Guggenheim | Buy |
| 2020-08-10 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Relay Therapeutics Inc Aktie (RLAY) Neueste Nachrichten
Relay Therapeutics has positive read from Celcuity data, says Barclays - Yahoo Finance
What is the risk reward ratio of investing in Relay Therapeutics Inc. stockMarket Forecast Opportunities Backed By Experts - jammulinksnews.com
When is Relay Therapeutics Inc. stock expected to show significant growthStock Strategy Tracker With High Returns - jammulinksnews.com
Price Floor Holding on Relay Therapeutics Inc. — Rebound PossibleProfit Focused Stock Screener Results Released - metal.it
Why is Relay Therapeutics Inc. stock attracting strong analyst attentionAchieve breakthrough profits with smart strategies - jammulinksnews.com
What are Relay Therapeutics Inc. company’s key revenue driversGet expert analysis on top stock picks - jammulinksnews.com
Does Relay Therapeutics Inc. stock perform well during market downturnsAchieve breakthrough investment performance - jammulinksnews.com
How does Relay Therapeutics Inc. compare to its industry peersMaximize gains with proven stock analysis - jammulinksnews.com
Is Relay Therapeutics Inc. a growth stock or a value stockGet daily updates on the hottest stocks - jammulinksnews.com
What catalysts could drive Relay Therapeutics Inc. stock higher in 2025Invest in high-yield stocks with confidence - jammulinksnews.com
What are the latest earnings results for Relay Therapeutics Inc.Build wealth steadily with smart stock selection - jammulinksnews.com
Is Relay Therapeutics Inc. stock overvalued or undervaluedExceptional stock performance - jammulinksnews.com
Why Relay Therapeutics Inc. stock attracts strong analyst attentionCapital Efficient Investment Tips - metal.it
What analysts say about Relay Therapeutics Inc. stockExceptional growth trajectory - PrintWeekIndia
RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now? - Yahoo Finance
Is Relay Therapeutics Inc. a good long term investmentFree Investment Community - PrintWeekIndia
When is the best time to buy Relay Therapeutics Inc. stockFree Consultation - jammulinksnews.com
Will Relay Therapeutics Inc. stock benefit from AI tech trendsFree Stock Index Interpretation - jammulinksnews.com
What drives Relay Therapeutics Inc. stock priceTremendous growth potential - PrintWeekIndia
Relay Therapeutics Inc. Stock Analysis and ForecastExceptional earning trajectories - jammulinksnews.com
what makes relay therapeutics inc. stock price move sharplyTargeted 200 Percent Gain - Newser
Is Relay Therapeutics Inc. stock overhyped or has real potentialLong Term Secure Gain Stocks - Newser
Is Relay Therapeutics Inc. stock a good hedge against inflationFree Stock Market Insider Analysis - Newser
Finanzdaten der Relay Therapeutics Inc-Aktie (RLAY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Relay Therapeutics Inc-Aktie (RLAY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Rahmer Peter | See remarks |
Apr 30 '25 |
Sale |
3.00 |
10,739 |
32,217 |
390,081 |
| Rahmer Peter | See remarks |
Apr 28 '25 |
Sale |
3.17 |
1,364 |
4,324 |
400,820 |
| Catinazzo Thomas | Chief Financial Officer |
Apr 30 '25 |
Sale |
3.00 |
12,943 |
38,829 |
355,376 |
| Catinazzo Thomas | Chief Financial Officer |
Apr 29 '25 |
Sale |
3.23 |
3,558 |
11,492 |
368,319 |
| Catinazzo Thomas | Chief Financial Officer |
Apr 28 '25 |
Sale |
3.17 |
2,690 |
8,527 |
371,877 |
| Bergstrom Donald A | President, R&D |
Apr 30 '25 |
Sale |
3.00 |
27,472 |
82,416 |
583,490 |
| Bergstrom Donald A | President, R&D |
Apr 28 '25 |
Sale |
3.17 |
4,090 |
12,965 |
610,962 |
| Adams Brian | Chief Legal Officer |
Apr 30 '25 |
Sale |
3.00 |
12,943 |
38,829 |
391,385 |
| Adams Brian | Chief Legal Officer |
Apr 28 '25 |
Sale |
3.17 |
1,644 |
5,211 |
404,328 |
8.87%
2.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):